Please assess the completion status of the following clinical trial:

Trial Title: Banding Ligation With Carvedilol Versus Carvedilol for the Prevention of First Bleeding

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Cirrhosis with esophageal varices are larger than F2.~2. No history of variceal bleeding.~3. In three months have not implemented preventive esophageal variceal ligation. (4)age 20yrs～75yrs.~Exclusion Criteria:~1. Association with HCC or other cancers .~2. Refractory ascites.~3. Jaundice, bilirubin \> 5mg/dl.~4. Encephalopathy.~5. Cr.\>3mg/dL.~6. A-V,block bradycardia (PR \< 60/mim).~7. Hypotension systolic blood pressure\<95/mmHg .~8. Refusal to participate.~9. Carvedilol allergy~10. Second degree-third degree Atrio-ventricular block.~11. Bradycardia.~12. WPWsyndrome~13. Hypotension~14. Psychogenic shock.~15. Asthma. All the patients are randomized based on a random number.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- EVL + carvedilol (Type: EXPERIMENTAL): EVL is performed for 2-3 times carvedilol 6.25mg-12.5 mg per day
- carvedilol (Type: ACTIVE_COMPARATOR): carvedilol 6.25-12.5 mg per day

Based on this trial design, predict the completion outcome and termination type (if applicable).